ClickHouse Acquires LibreChat to Democratize AI-Driven Analytics Through the Open-Source Agentic Data Stack
4.11.2025 18:00:00 CET | Business Wire | Press release
ClickHouse, Inc., the company behind the world’s fastest and most popular real-time analytics database, today announced the acquisition of LibreChat, a leading open-source AI chat platform that provides a unified interface for interacting with large language models (LLMs). The acquisition brings LibreChat founder Danny Avila and his team to ClickHouse.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104505230/en/
ClickHouse acquires LibreChat: Introducing the open-source Agentic Data Stack
Together, ClickHouse and LibreChat form the foundation of the open-source Agentic Data Stack, empowering teams to deploy AI agents that analyze and act on large datasets through natural language. This shift to agentic analytics is already transforming how organizations such as Shopify, Daimler Truck, Fetch, and cBioPortal leverage their data, demonstrating the immediate value in real-world applications.
At Shopify, LibreChat has become central to internal AI workflows. “LibreChat powers reflexive AI use across Shopify. With near universal adoption and thousands of custom agents, teams use it to solve real problems, increase productivity, and keep the quality bar high. By connecting more than 30 internal MCP servers, it democratizes access to critical information across the company,” said Matt Burnett, Senior Engineer at Shopify.
In healthcare, cBioPortal uses the combined ClickHouse and LibreChat Agentic Data Stack to unlock new research capabilities. "By leveraging the ClickHouse, MCP, and LibreChat stack, we rapidly delivered a prototype to cBioPortal users that empowered them to ask entirely new questions about cancer genomics and treatment trajectories, get quick answers, and explore data in ways not possible through the existing UI," said Ino de Bruijn, Manager Bioinformatics Software Engineering at cBioPortal. "It puts discovery at cancer researchers' fingertips."
This LibreChat acquisition comes as enterprises rapidly adopt agentic analytics to democratize data access and accelerate time-to-insight. Fetch, a leading mobile rewards platform, built its FAST AI-powered analytics product on ClickHouse to transform household purchase behavior into actionable business intelligence. "We see agentic analytics as the future of data interaction, enabling more intuitive, dynamic, and impactful use of information," said Sam Corzine, Director of Machine Learning at Fetch. "With its unmatched speed and scalability, ClickHouse is well-positioned to power this new generation of agentic experiences, and we're thrilled to grow our partnership together."
ClickHouse leverages agentic analytics internally with LibreChat-and-ClickHouse-powered DWAINE (Data Warehouse AI Natural Expert), an agent that now handles approximately 70% of data warehouse queries for over 200 users, processing 33 million LLM tokens daily as of October 2025—up from 15 million just months after launch.
"What impressed me most is LibreChat's vibrant community that continuously innovates," said Dmitry Pavlov, Director of Engineering at ClickHouse. "The synergy between ClickHouse Cloud's blazing-fast query performance and LibreChat's flexible, multi-LLM architecture is unlocking a new generation of data analysis agents - real-time, secure, powerful, and accessible."
For existing LibreChat deployments, operations continue unchanged with ongoing investment in the open-source project and community. ClickHouse users will gain access to enhanced integration capabilities, including native LibreChat experience alongside ClickHouse Cloud instances, extended data visualization support, enterprise-grade security and governance, and a tailored semantic layer. These investments will ensure that the Agentic Data Stack is fully enterprise-ready, meeting the requirements of the world's most demanding organizations.
“Every breakthrough in data technology has been about reducing the distance between questions and answers. By joining forces with LibreChat, we’re tackling this distance. Now, any user can talk directly to petabytes of data and get instant, actionable insights,” said Aaron Katz, CEO of ClickHouse. “As AI agents proliferate across every industry, the companies that win will be those that can seamlessly connect human intelligence with machine-scale data processing. The future of analytics isn’t just dashboards, it’s intelligent agents that interpret data, trigger workflows, and power real-time decisions. The ClickHouse Agentic Data Stack makes that future available today.”
About ClickHouse
ClickHouse is a fast, open-source columnar database management system built for real-time data processing and analytics at scale. Engineered for high performance, ClickHouse Cloud delivers exceptional query speed and concurrency, making it ideal for applications that demand instant insight from massive volumes of data. As AI agents become increasingly embedded in software and are generating far more frequent and complex queries, ClickHouse brings a high-throughput, low-latency engine, purpose-built to meet this challenge. Trusted by leading companies like Sony, Tesla, Anthropic, Memorial Sloan Kettering, Lyft, and Instacart, ClickHouse helps teams unlock insights and drive smarter decisions with a scalable, efficient, and modern data platform. For more information, visit clickhouse.com.
About LibreChat
LibreChat is a leading open-source AI chat platform offering a unified interface for interacting with multiple large language models. The platform gives users and organizations complete control over their data, agents, and conversations while supporting enterprise-grade deployments at scale.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251104505230/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom